You are here

Share:

Diagnostic Assays for the Detection of Thyroid Cancer

Summary
The Eunice Kennedy Shriver National Institute of Child and Human Development’s (NICHD) Pediatric Growth and Nutrition Branch seek partners to co-develop a diagnostic assay to detect thyroid cancer.
NIH Reference Number
E-016-2013
Product Type
Keywords
  • Thyroid cancer
  • Thyroid
  • Midkine
  • Pleiotrophin
  • Commercial diagnostic kit
Collaboration Opportunity
This invention is available for licensing.
Contact
Description of Technology

Thyroid cancer represents a disease particularly amenable to improved methods of diagnosis. Current methods of diagnosis determining the malignancy of thyroid nodules involve needle biopsies and microscopic inspections which are subjective, often leading to inconclusive results and the need for surgery. Therefore, there is a need for improved methods of diagnostic accuracy.

NIH scientists have developed two ELISA assays for distinguishing malignant versus benign thyroid biopsy samples. The ELISA assays quantify the amount of midkine and pleiotrophin present in thyroid tissue samples collected from fine needle aspirates. Midkine and pleiotrophin are both low molecular weight growth factors that are over-expressed in many cancerous tissues. Application of this technique for the identification of thyroid cancer represents a first-in-class diagnostic for this disease.

Potential Commercial Applications
  • A diagnostic kit for the detection of thyroid cancer.
Competitive Advantages

• High assay sensitivity permits the use of small tissue samples (e.g., fine needle aspirates of nodules)

• Assay can incorporate commercially-available midkine or pleiotrophin antibodies.

• Assay relies on proven ELISA detection technology.

Inventor(s)

Jeffrey Baron (NICHD), Youn Hee Jee

Development Stage
Patent Status
  • U.S. Patent Issued: U.S. Patent Number 9664682
  • U.S. Patent Issued: U.S. Patent Number 9658233
  • Foreign Filed: US - Patent Application 15/435,880
Therapeutic Area
Updated
Friday, October 6, 2017